Astria Therapeutics Inc (NASDAQ: ATXS) started the day on Thursday, with a price decrease of -3.85% at $9.75, before settling in for the price of $10.14 at the close. Taking a more long-term approach, ATXS posted a 52-week range of $4.75-$16.90.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 0.00%. Meanwhile, its Annual Earning per share during the time was 39.84%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 29.93%. This publicly-traded company’s shares outstanding now amounts to $56.43 million, simultaneously with a float of $48.25 million. The organization now has a market capitalization sitting at $550.23 million. At the time of writing, stock’s 50-day Moving Average stood at $10.99, while the 200-day Moving Average is $11.11.
Astria Therapeutics Inc (ATXS) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Astria Therapeutics Inc’s current insider ownership accounts for 14.49%, in contrast to 87.20% institutional ownership. According to the most recent insider trade that took place on Apr 01 ’24, this organization’s Chief Medical Officer sold 10,000 shares at the rate of 13.59, making the entire transaction reach 135,939 in total value, affecting insider ownership by 0. Preceding that transaction, on Feb 01 ’24, Company’s Director bought 2,481,350 for 12.09, making the whole transaction’s value amount to 29,999,522. This particular insider is now the holder of 4,873,721 in total.
Astria Therapeutics Inc (ATXS) Earnings and Revenue Records
Astria Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 29.93% and is forecasted to reach -1.80 in the upcoming year.
Astria Therapeutics Inc (NASDAQ: ATXS) Trading Performance Indicators
Let’s observe the current performance indicators for Astria Therapeutics Inc (ATXS). It’s Quick Ratio in the last reported quarter now stands at 22.38. The Stock has managed to achieve an average true range (ATR) of 0.63.
In the same vein, ATXS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.09, a figure that is expected to reach -0.45 in the next quarter, and analysts are predicting that it will be -1.80 at the market close of one year from today.
Technical Analysis of Astria Therapeutics Inc (ATXS)
If we take a close look at the recent performances of Astria Therapeutics Inc (NASDAQ: ATXS), its last 5-days Average volume was 0.45 million that shows plunge from its year to date volume of 0.6 million. During the previous 9 days, stock’s Stochastic %D was recorded 47.43% While, its Average True Range was 0.60.
Raw Stochastic average of Astria Therapeutics Inc (ATXS) in the period of the previous 100 days is set at 26.45%, which indicates a major fall in contrast to 49.46% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 54.07% that was lower than 63.79% volatility it exhibited in the past 100-days period.
